Orforglipron vs Retatrutide: What the Research Shows
Orforglipron and Retatrutide side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Orforglipron if…
- you want an FDA-approved oral option: Foundayo (orforglipron) is labelled, with diet and activity, to reduce excess body weight in adults with obesity or with overweight plus a weight-related condition[7]
- you want an oral option with randomized weight-loss data: Body weight changed by -7.5% (6 mg), -8.4% (12 mg) and -11.2% (36 mg) with orforglipron vs -2.1% with placebo at week 72.[15]
- you are tested in sport and want to avoid a WADA-prohibited substance: Retatrutide is prohibited by WADA at all times (check orforglipron's own status separately)[6]
Consider Retatrutide if…
- you are weighing an investigational option (no FDA-approved product yet): the TRIUMPH trial reported mean weight change of -25.0% with the 12-mg dose versus -3.9% with placebo[1]
- you want to know where approval stands: Lilly states it plans to submit a Biologics License Application to the FDA, a submission plan and not an approval[16]
Spec comparison
Showing 8 of 11 fields where the two differ. Category, PCAC vote, Jul 2026, Evidence strength are the same or both unknown.
| Field | Orforglipron | Retatrutide |
|---|---|---|
| Class | Oral small-molecule GLP-1 agonist | GLP-1 / GIP / glucagon triple agonist |
| Also called | Foundayo, orfo | reta, GLP-3, LY3437943 |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | FDA approved (Foundayo, Apr 2026) | Investigational · phase 3 |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. | Prohibited by WADA (S0)Retatrutide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change. |
| Half-life | approximately 29 to 49 hoursoral · FDA label (Foundayo) | approximately 6 dayssubcutaneous · Lancet 2022, PMID 36354040 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41275875 | Human RCT evidence, 4 of 4Strongest: The New England journal of medicine 2026, PMID 42814954 |
| Human studies we summarised | 14 human (13 randomized or controlled) of 15 summarised | 11 human (11 randomized or controlled) of 16 summarised |
| Typical study doses |
|
|
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026; 31 Mar 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
An approved pill and an unapproved weekly injection
In retatrutide's phase 3 obesity trial, the 12-mg group's mean body weight change was -25.0%, against -3.9% on placebo.[1]
In the orforglipron obesity trial, 54.6% of the 36-mg group lost 10% or more of body weight, 36.0% lost 15% or more, and 18.4% lost 20% or more.[15]
Retatrutide's phase 3 trial also had primary outcomes in 574 participants with knee osteoarthritis and 243 with obstructive sleep apnea.[1]
In retatrutide's phase 2 trial, the most common adverse events were gastrointestinal, dose-related and mostly mild to moderate.[17]
In the same phase 2 trial, heart rate rose dose-dependently, peaking at 24 weeks and declining afterwards.[17]
Approval and format
The FDA's drug database lists Foundayo (orforglipron) as a prescription tablet.[18]
No retatrutide product appears in Drugs@FDA.[19]
The Foundayo label gives an elimination half-life of approximately 29 to 49 hours after an oral dose.[7]
WADA's list prohibits at all times any substance with no current approval for human therapeutic use, such as drugs in clinical development. That catch-all is the class that covers an unapproved drug like retatrutide.[6]
Common questions
Is retatrutide stronger than orforglipron?
There is no direct comparison. In its own phase 3 obesity trial, retatrutide's 12-mg group lost a mean 25.0% of body weight versus 3.9% on placebo.[1]
Which is available now, orforglipron or retatrutide?
Only orforglipron: it is listed in Drugs@FDA as Foundayo, while retatrutide has no match.[18]
Orforglipron vs retatrutide: which has fewer side effects?
Both lead with gastrointestinal effects. No trial compares them, so rates cannot be read across trials.[15]
Sources
- 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
- 4Orforglipron approved as FoundayoFDA · 2026fda.govAccessed 2 Oct 2026
- 5Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 6World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 7These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO. FOUNDAYO (orforglipron) tablets, for oral use Initial FDA label (Foundayo), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 8Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
- 9Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 41765029Accessed 2 Oct 2026
- 10Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.Lancet (London, England) · 2026PMID 42259339Accessed 2 Oct 2026
- 11LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
- 12Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
- 13Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
- 14PubMed search: (orforglipron[tiab] OR LY3502970[tiab] OR Foundayo[tiab]) AND (retatrutide[tiab] OR LY3437943[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
- 16Official web pageOfficial web page · web page
- 17Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
- 18Drugs@FDA (openFDA) search: active ingredient "orforglipron"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 19Drugs@FDA (openFDA) search: active ingredient "retatrutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.